Feed
Reuters•6h agoSource •84Low

GSK stops development of chronic cough drug after late-stage trial miss

The News

GSK has halted development of a chronic cough drug after it failed to meet its goals in a late-stage clinical trial. The decision underscores the difficulty in finding effective treatments for chronic cough. No further details on the drug or trial results were provided in the announcement.

Infographic

No infographic was generated for this story. GreyNews is not leaving this spinning indefinitely.

The Analysis

Intelligence Brief

Analyzed · Low confidence (25%)

Quality-gated

Same as the summary above — this brief adds the distinct fields below.

Needs review(49/100)Claims missingHeld back by the standards gate — not yet accepted for durable Brain/KG learning.
SummarySolidAnglesSolidEvidenceBlockedClaimsBlockedUncertaintyWeakPredictionsSolidBiasSolidBrain syncAdvisory
Why it matters

GSK likely incurred costs from the late-stage trial.

Evidence

0 verified / 0 claims

Uncertainty

No flagged uncertainty yet.

Watch next

No forecast extracted yet.

Brain noteGreyMatter sync is quality-weighted until the analysis has enough evidence and source reliability for durable Brain/KG learning.

Key findings

Economicscore: 60
  • GSK likely incurred costs from the late-stage trial.
  • Missed potential market for chronic cough drug.

Trust Breakdown

Emotional languageLow
Source reliabilityHigh
Facts checked65% claims verified
Source reliability
Reuters →
Developing track record
Not enough verified claims to calculate accuracy yet
Based on economic claims verified against official data (BLS, World Bank, IMF). See full breakdown →

Plain English

Loaded language removed

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOTJyXzZma0ZYNnRvRjM1c0kzLWg1eEVWSXdkNVRHTlFZR29CMzFReWlicTZiX0ZUOEdzbTB0UmM4VmlRMTdieHNHT2I5RjJPWHR3X0swbF9Ua0xLTXVfdmVCWDM4aE5mRkJHWTM3d1JOcjFxLWJsQjFVdHQtRHF0dTRud3Z4cXlyR25ZVWhkN2lGTEZrUVJJQ0FCZ0Q4SDU5SE1HcE1NTUdzaUtsQm1aWm5tVFA2SlNKU3hfSWw5R2N0SWlKSDQ0eVBxeTBMTXA3?oc=5" target="_blank">GSK stops development of chronic cough drug…

Emotionally neutral rewrite. Same facts, calmer framing.

What's next

This angle has contested claims

Read original on Reuters
AI-assisted analysis · How we work →